17.04

0.83% 0.14

After Hours: 17.04

Neuropace Inc (NPCE)

Overview News Price History Financials Discussions Forecast

Neuropace Inc stock is traded at $17.04, with a volume of 115.46K. It is up +0.83% in the last 24 hours and up +16.31% over the past month. NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Previous Close:

$16.90

Open:

$17.19

24h Volume:

115.46K

Relative Volume:

0.61

Market Cap:

$578.52M

Revenue:

$99.99M

Net Income/Loss:

$-21.47M

P/E Ratio:

-25.83

EPS:

-0.6597

Net Cash Flow:

$-11.34M

1W Performance:

+0.89%

1M Performance:

+16.31%

6M Performance:

+31.28%

1Y Performance:

+47.79%

1-Day Range:

$16.69

$17.26

1-Week Range:

$15.98

$17.85

52-Week Range:

$7.5625

$18.98

Neuropace Inc Stock (NPCE) Company Profile

Name

Neuropace Inc

Sector

Healthcare (1106)

Industry

Medical Devices (142)

Phone

(650) 237-2700

Address

455 N. BERNARDO AVENUE, MOUNTAIN VIEW

Employee

209

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

NPCE's Discussions on Twitter

Compare NPCE vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NPCE Neuropace Inc	17.04	573.76M	99.99M	-21.47M	-11.34M	-0.6597
ABT Abbott Laboratories	87.17	152.48B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	295.25	111.40B	25.27B	3.34B	4.57B	8.6358
MDT Medtronic Plc	77.79	100.53B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	55.98	84.50B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	82.91	48.04B	6.30B	1.07B	1.34B	1.8406

Neuropace Inc Stock (NPCE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-25	Initiated	H.C. Wainwright	Buy
Jan-21-25	Initiated	UBS	Buy
Mar-14-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-30-24	Initiated	Leerink Partners	Outperform
Nov-10-23	Initiated	Cantor Fitzgerald	Overweight
Aug-24-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-22-23	Initiated	Lake Street	Buy
Apr-06-22	Initiated	Wolfe Research	Outperform
Jan-19-22	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-07-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-11-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-18-21	Initiated	Robert W. Baird	Outperform
May-17-21	Initiated	JP Morgan	Overweight
May-17-21	Initiated	Morgan Stanley	Overweight
May-17-21	Initiated	SVB Leerink	Outperform
May-17-21	Initiated	Wells Fargo	Overweight

View All

Neuropace Inc Stock (NPCE) Latest News

11:39 AM

NeuroPace (NPCE) Projected to Post Quarterly Earnings on Tuesday - MarketBeat

11:39 AM

May 03, 2026

Liquidity Mapping Around (NPCE) Price Events - Stock Traders Daily

May 03, 2026

May 01, 2026

RNS System delivers life changing outcomes in 3 year post approval study, NeuroPace Inc reveals - Traders Union

May 01, 2026

Apr 29, 2026

NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026 - Business Wire

Apr 29, 2026

Apr 28, 2026

NeuroPace Inc warns less than 5 percent seizure reduction when medications fail twice - Traders Union

Apr 28, 2026

Apr 27, 2026

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026 - BioSpace

Apr 27, 2026

Here's why you should add NeuroPace stock to your portfolio now - MSN

Apr 27, 2026

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study Results in Neurology and NAUTILUS Presentation at AAN 2026 - Investing News Network

Apr 27, 2026

NPCE Neuropace posts far narrower than expected Q4 2025 loss even as shares dip slightly today.Institutional Grade Picks - Newser

Apr 27, 2026

Wall Street analysts see a 41.29% upside in NeuroPace (NPCE): Can the stock really move this high? - MSN

Apr 27, 2026

Apr 26, 2026

NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Apr 26, 2026

Apr 22, 2026

NPCE Neuropace posts smaller than expected Q4 2025 loss, sending shares 2.38 percent higher in today’s trading. - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026

Why (NPCE) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Apr 22, 2026

Apr 21, 2026

NeuroPace (NASDAQ: NPCE) plans 2026 virtual vote on board and auditor - Stock Titan

Apr 21, 2026

NeuroPace Inc introduces RNS System as alternative for patients unresponsive to epilepsy medications - Traders Union

Apr 21, 2026

Apr 19, 2026

NeuroPace Inc reports 77 percent drop in GTCs with NAUTILUS trial data - Traders Union

Apr 19, 2026

Apr 18, 2026

NeuroPace Inc unveils NAUTILUS Study results at AAN Annual Meeting - Traders Union

Apr 18, 2026

Apr 17, 2026

NeuroPace Inc unveils NAUTILUS Study findings on neuromodulation for drug-resistant IGE - Traders Union

Apr 17, 2026